Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)

SHE:002422 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	4,093	3,974	4,675	4,729	2,920	2,772
Short-Term Investments	-	555.65	579.39	-	-	-
Trading Asset Securities	2,231	1,921	1,691	448.11	359.53	265.42
Cash & Short-Term Investments	6,324	6,451	6,946	5,177	3,279	3,037
Cash Growth	-7.42%	-7.13%	34.17%	57.88%	7.96%	34.79%
Accounts Receivable	6,139	6,098	6,120	7,198	6,463	7,432
Other Receivables	186.48	126.17	162.49	256.3	221.92	117.57
Receivables	6,326	6,224	6,283	7,454	6,685	7,549
Inventory	3,828	3,801	3,840	3,214	3,363	3,468
Other Current Assets	2,011	1,460	1,222	804.22	681.4	645.3
Total Current Assets	18,489	17,936	18,290	16,649	14,009	14,700
Property, Plant & Equipment	12,886	13,012	12,086	11,331	11,614	11,987
Long-Term Investments	4,377	4,281	3,992	3,809	3,409	2,751
Goodwill	98.66	98.66	98.66	98.66	98.66	158.45
Other Intangible Assets	1,233	1,223	1,277	1,201	1,063	987.8
Long-Term Deferred Tax Assets	432.94	423.03	342.57	618.21	581.57	552.18
Long-Term Deferred Charges	82.18	83.06	75.72	233.81	365.28	516.12
Other Long-Term Assets	227.65	260.11	293.17	264.34	400.05	330.62
Total Assets	37,826	37,316	36,455	34,206	31,540	31,983
Accounts Payable	2,439	2,574	2,539	2,244	2,156	1,861
Accrued Expenses	307.45	2,259	2,028	1,973	1,610	2,525
Short-Term Debt	3,088	2,457	3,458	4,499	5,183	5,067
Current Portion of Long-Term Debt	790.41	808.4	746.86	2,012	3,199	2,208
Current Portion of Leases	-	62.56	40.53	17.31	11.57	-
Current Income Taxes Payable	245.37	140.11	162.74	108.18	119.48	92.6
Current Unearned Revenue	485.39	645.45	839.83	360.36	264.69	187.88
Other Current Liabilities	1,736	190.71	177.87	889.3	864.55	316.52
Total Current Liabilities	9,093	9,138	9,993	12,104	13,408	12,258
Long-Term Debt	196	342	2,649	4,704	3,506	5,100
Long-Term Leases	525.26	537.46	245.23	51.74	16.18	-
Long-Term Unearned Revenue	299.51	294.65	288.21	208.88	225.73	362.07
Long-Term Deferred Tax Liabilities	278.96	266.09	264.1	265.83	254.32	260.55
Other Long-Term Liabilities	3.04	-	0.08	-	-	-
Total Liabilities	10,395	10,578	13,439	17,335	17,410	17,980
Common Stock	1,598	1,601	1,499	1,422	1,425	1,439
Additional Paid-In Capital	7,713	7,732	6,144	3,673	3,581	3,889
Retained Earnings	13,807	13,222	11,973	10,416	9,328	8,675
Treasury Stock	-131.7	-191.83	-215.14	-237.08	-399.98	-499.88
Comprehensive Income & Other	108.09	115.84	272.07	459.82	-77.49	-3.51
Total Common Equity	23,094	22,480	19,672	15,734	13,857	13,499
Minority Interest	4,336	4,259	3,343	1,137	272.62	503.99
Shareholders' Equity	27,431	26,738	23,016	16,871	14,129	14,003
Total Liabilities & Equity	37,826	37,316	36,455	34,206	31,540	31,983
Total Debt	4,600	4,207	7,139	11,285	11,916	12,375
Net Cash (Debt)	1,724	2,243	-193.52	-6,108	-8,637	-9,337
Net Cash Per Share	1.08	1.42	-0.13	-4.12	-6.11	-6.53
Filing Date Shares Outstanding	1,579	1,591	1,488	1,412	1,406	1,430
Total Common Shares Outstanding	1,579	1,591	1,488	1,412	1,406	1,430
Working Capital	9,397	8,798	8,297	4,545	600.44	2,442
Book Value Per Share	14.63	14.13	13.22	11.15	9.85	9.44
Tangible Book Value	21,763	21,158	18,297	14,434	12,695	12,353
Tangible Book Value Per Share	13.78	13.30	12.29	10.23	9.03	8.64
Buildings	-	7,464	6,557	6,160	6,057	5,932
Machinery	-	13,101	11,592	11,348	11,078	10,793
Construction In Progress	-	1,204	2,045	1,126	922.73	840.67

Source: S&P Global Market Intelligence. Standard template. Financial Sources.